查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1712513

全球神经诊断市场 - 2025-2033

Global Neurodiagnostics Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球神经诊断市场规模达到 93.5 亿美元，预计到 2033 年将达到 211.7 亿美元，在 2025-2033 年预测期内的复合年增长率为 9.6%。

神经诊断学是医学诊断学的一个专门分支，专注于透过使用各种诊断技术和工具来识别、监测和评估神经系统疾病。这些技术主要用于评估神经系统（包括大脑、脊髓和周边神经）的功能、结构和整体健康状况。

神经诊断学包括电生理和基于影像的测试，以及在某些情况下的分子诊断，以协助医疗保健提供者诊断与中枢和周围神经系统相关的疾病。这些疾病包括癫痫、阿兹海默症、帕金森氏症、多发性硬化症、脑瘤、创伤性脑损伤 (TBI) 和睡眠障碍等神经系统疾病。

市场动态：

驾驶员和约束装置

神经诊断技术的不断进步极大地推动了神经诊断市场的成长。

不断进步的技术极大地推动了神经诊断市场的成长，使其能够进行早期诊断、提高准确性、改善患者治疗效果并扩大诊断工具的可及性。这些创新也带来了具有成本效益的解决方案、改善了患者护理并制定了针对神经系统疾病的个人化治疗方案。因此，主要和新兴市场参与者正专注于技术先进的神经诊断，这进一步推动了市场的成长

例如，2025 年 4 月，神经诊断开发商 Cadwell Industries 发布了其最新的 Sierra 软体版本，提供正在申请专利的同步超音波和肌电图 (EMG)。结合 Sierra Summit 电诊断系统和 Sierra NMUS1 整合超音波，此更新可将电生理资料和超音波成像即时呈现在单一萤幕上。其目的是协助针刺肌电图、化学去神经支配、神经阻断和水分离手术。

此外，2024 年 8 月，Natus Medical Incorporated 推出了 autoSCORE，这是第一个能够自动全面解释临床脑电图的人工智慧模型，其准确性可与医学专家媲美。 autoSCORE 应用程式有可能改善临床结果并提高数百万癫痫患者的护理价值。

神经诊断程序的高成本阻碍了市场成长

神经诊断程序的高成本对市场成长构成了重大障碍，限制了获得先进诊断工具的机会，尤其是在低收入地区和保险不足的患者中。这些成本阻碍了尖端神经诊断技术的广泛应用，延误了许多神经系统疾病患者的诊断和治疗。

许多先进的神经诊断技术，如脑电图、核磁共振成像、CT扫描和PET扫描，都需要昂贵的设备和维护，小型医院或诊所难以负担。除了设备成本外，这些手术本身也会给患者带来经济负担，特别是那些需要定期进行脑电图、核磁共振和 CT 扫描等诊断测试的患者。例如，视讯脑电图监测（保险前）的平均费用为 77,664 美元。

随着神经诊断市场不断扩大，解决这些成本挑战对于提高可及性和可负担性至关重要。经济高效的诊断工具、保险改革以及政府对先进神经诊断技术的资助等解决方案对于克服这些障碍并推动未来几年的市场成长至关重要。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第二章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品类型分类的程式码片段
  • 按应用程式截取的程式码片段
  • 最终用户的程式码片段
  • 按地区分类的片段

第三章：动态

  • 影响因素
    • 驱动程式
      • 神经诊断技术不断进步
      • 神经系统疾病盛行率上升
    • 限制
      • 神经诊断程序成本高昂
      • 神经系统疾病的复杂性
    • 机会
      • 与数位治疗学的整合
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大行销品牌的既定领导者
    • 拥有成熟产品的市场领导者
  • 最新进展与突破
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态

第五章：神经诊断市场（依产品类型）

  • 诊断设备
    • 脑电图（EEG）
    • 脑磁图（MEG）
    • MRI（磁振造影）
    • CT扫描（电脑断层扫描）
    • PET扫描（正子断层扫描）
    • 睡眠监测设备
    • 肌电图 (EMG) 设备
    • 多导睡眠图 (PSG) 设备
    • 其他的
  • 试剂、耗材和配件
    • 电极
    • 媒体
    • 缓衝区
    • 抗体
    • 溶剂
    • 其他的
  • 软体和应用程式

第六章：神经诊断市场（按应用）

  • 癫痫
  • 阿兹海默症
  • 帕金森氏症
  • 多发性硬化症
  • 睡眠障碍
  • 头痛疾病
  • 中风
  • 创伤性脑损伤（TBI）
  • 失智
  • 其他的

第七章：神经诊断市场（依最终用户）

  • 医院
  • 神经科诊所
  • 诊断实验室
  • 家庭护理设置
  • 其他的

第 8 章：神经诊断市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第九章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第十章：公司简介

  • GE HealthCare
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 关键进展
      • 併购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT分析
  • Siemens Healthineers AG
  • Koninklijke Philips NV
  • FUJIFILM Holdings
  • Thermo Fisher Scientific Inc.
  • Compumedics Limited
  • Natus
  • Stratus
  • Canon Medical Systems USA, Inc.
  • Nihon Kohden Corporation

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: MI5095

The global neurodiagnostics market size reached US$ 9.35 billion in 2024 and is expected to reach US$ 21.17 billion by 2033, growing at a CAGR of 9.6% during the forecast period 2025-2033.

Neurodiagnostics refers to a specialized branch of medical diagnostics that focuses on the identification, monitoring, and evaluation of neurological disorders through the use of various diagnostic techniques and tools. These techniques are primarily designed to assess the function, structure, and overall health of the nervous system, including the brain, spinal cord, and peripheral nerves.

Neurodiagnostics encompasses both electrophysiological and imaging-based tests, as well as molecular diagnostics in some cases, to assist healthcare providers in diagnosing conditions related to the central and peripheral nervous systems. These conditions include neurological diseases such as epilepsy, Alzheimer's disease, Parkinson's disease, multiple sclerosis, brain tumors, traumatic brain injuries (TBI), and sleep disorders, among others.

Market Dynamics: Drivers & Restraints

Rising technological advancements in neurodiagnostics are significantly driving the neurodiagnostics market growth.

Rising technological advancements are significantly driving the growth of the neurodiagnostics market by enabling early diagnosis, improving accuracy, enhancing patient outcomes, and expanding accessibility to diagnostic tools. These innovations are also leading to cost-effective solutions, improved patient care, and the development of personalized treatment plans for neurological diseases. Thus, the key and emerging market players are focusing on technologically advanced neurodiagnostics, which are further boosting the growth of the market

For instance, in April 2025, Neurodiagnostics developer Cadwell Industries launched its latest Sierra software release, providing patent-pending, synchronized ultrasound and electromyography (EMG). Combined with the Sierra Summit electrodiagnostic system and Sierra NMUS1 integrated ultrasound, the update brings electrophysiological data and ultrasound imaging together in real time on a single screen. This aims to assist in needle EMG, chemodenervation, nerve block, and hydrodissection procedures.

Additionally, in August 2024, Natus Medical Incorporated launched autoSCORE, the first-of-its-kind artificial intelligence model capable of automatic and comprehensive clinical EEG interpretation, providing accuracy on par with medical experts. The autoSCORE application has the potential to improve clinical outcomes and the value of care for the millions suffering from epilepsy.

High cost of neurodiagnostic procedures hampering the market growth

The high costs associated with neurodiagnostic procedures represent a significant barrier to market growth, limiting access to advanced diagnostic tools, especially in low-income regions and for underinsured patients. These costs hinder the widespread adoption of cutting-edge neurodiagnostic technologies, delaying diagnosis and treatment for many individuals with neurological conditions.

Many of the advanced neurodiagnostic technologies, such as EEG, MRI, CT scans, and PET scans, require expensive equipment and maintenance, making them difficult for smaller hospitals or clinics to afford. In addition to the costs of equipment, the procedures themselves can be financially burdensome for patients, particularly for those requiring regular diagnostic tests such as EEG, MRI, and CT scans. For instance, video EEG monitoring costs an average of $77,664 before insurance.

As the neurodiagnostics market continues to expand, addressing these cost challenges will be crucial for improving accessibility and affordability. Solutions like cost-effective diagnostic tools, insurance reforms, and government funding for advanced neurodiagnostic technologies are essential to overcome these barriers and drive market growth in the coming years.

Segment Analysis

The global neurodiagnostics market is segmented based on product type, application, end-user, and region.

Product Type:

The diagnostic equipment segment is expected to dominate the neurodiagnostics market with the highest market share.

The diagnostic equipment segment is the dominant segment in the neurodiagnostics market due to its crucial role in early detection, accurate diagnosis, and monitoring of neurological diseases. Technologies such as MRI, CT scans, EEG, and PET scans are essential tools for clinicians in diagnosing neurological disorders, including stroke, Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors.

The continued development of advanced imaging systems and non-invasive diagnostic tools has solidified the diagnostic equipment segment as the leading contributor to the market. Moreover, the novel product launches by key and emerging players by regulatory support are also boosting the segment growth.

For instance, in October 2024, Natus Medical Incorporated submitted an FDA 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its Natus point-of-care EEG device. The rapid-deploy decision-support tool is designed to quickly help identify non-convulsive seizures (NCSs) and status epilepticus in acute care environments, supporting rapid intervention and streamlining treatment decisions to improve patient outcomes.

This point-of-care EEG system leverages Natus's leading NeuroWorks software platform to provide a seamless and familiar review experience with remote neurologist collaboration, 24/7 from any web browser. NeuroWorks EEG systems are trusted by more health systems and small practices around the world. With its unparalleled expertise in complex IT environments, Natus will utilize a leading cybersecurity-certified cloud platform to ensure patient data security.

Geographical Analysis

North America is expected to hold a significant position in the global neurodiagnostics market with the highest market share

The North America region is the dominant market for neurodiagnostics, driven by factors such as advanced healthcare infrastructure, high healthcare spending, widespread access to cutting-edge neurodiagnostic technologies, and a high prevalence of neurological diseases. This dominance is also supported by the presence of leading healthcare providers, manufacturers of diagnostic equipment, and ongoing advancements in research and development (R&D).

According to the Alzheimer's Association, nearly 7 million Americans are living with Alzheimer's. By 2050, this number is projected to rise to nearly 13 million. This rising incidence of neurological disorders in North America, including Alzheimer's disease, Parkinson's disease, stroke, epilepsy, and multiple sclerosis, is a significant factor propelling the growth of the neurodiagnostics market. As the prevalence of neurological conditions is increasing, there is a greater need for accurate diagnostic tools.

North America is at the forefront of technological innovation in the neurodiagnostics market, with continuous advancements in diagnostic tools that improve both the accuracy and efficiency of neurological diagnoses. These innovations include AI-powered diagnostic tools and wearable EEG devices, which are transforming how neurological conditions are diagnosed and managed.

For instance, in November 2024, LVIS Corporation launched NeuroMatch Access, an artificial-intelligence (AI)-driven platform for electroencephalogram (EEG) data analysis in the US. The Silicon Valley, US-based company's platform, which received 510(k) clearance from the US Food and Drug Administration (FDA) in May 2023, uses AI to review and interpret EEG signals by removing unwanted artifacts. EEG is used to measure the electrical activity of the brain and can aid in the diagnosis of conditions, including brain damage and epilepsy.

Competitive Landscape

Top companies in the neurodiagnostics market include GE HealthCare, Siemens Healthineers AG, Koninklijke Philips N.V., FUJIFILM Holdings, Thermo Fisher Scientific Inc., Compumedics Limited, Natus, Stratus, Canon Medical Systems USA, Inc., Nihon Kohden Corporation, and among others.

Key Developments

  • In April 2025, Cadwell Industries launched its latest Sierra software release, providing patent-pending, synchronized ultrasound and electromyography (EMG). Combined with the Sierra Summit electrodiagnostic system and Sierra NMUS1 integrated ultrasound, the update brings electrophysiological data and ultrasound imaging together in real time on a single screen. This aims to assist in needle EMG, chemodenervation, nerve block, and hydrodissection procedures.
  • In October 2023, Ceribell, Inc. announced the commercial release of its new AI algorithm, ClarityPro, accompanying the availability of potential additional reimbursement for eligible Medicare patients. ClarityPro is an AI-based software algorithm within the Ceribell EEG system that analyzes EEG waveforms to diagnose electrographic status epilepticus (ESE).
  • In October 2023, BeCareLink introduced a new quantitative and artificial intelligence (AI)-enabled app called BeCare Neuro Link, the new mobile application is intended for the remote, objective, and comprehensive assessment of neurologic patients or those with potential neurologic conditions. It can be used for screening as-of-yet-undiagnosed neurologic conditions as well as monitoring the response to treatment for known neurologic disorders.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global neurodiagnostics market report delivers a detailed analysis with 62 key tables, more than 61 visually impactful figures, and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Technological Advancements in Neurodiagnostics
      • 3.1.1.2. Rising Prevalence of Neurological Disorders
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Neurodiagnostic Procedures
      • 3.1.2.2. Complexity of Neurological Conditions
    • 3.1.3. Opportunity
      • 3.1.3.1. Integration with Digital Therapeutics
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established Leaders with Largest Marketing Brand
    • 4.1.3. Market Leaders with Established Products
  • 4.2. Latest Developments and Breakthroughs
  • 4.3. Regulatory and Reimbursement Landscape
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia Pacific
    • 4.3.4. South America
    • 4.3.5. Middle East & Africa
  • 4.4. Porter's Five Forces Analysis
  • 4.5. Supply Chain Analysis
  • 4.6. Patent Analysis
  • 4.7. SWOT Analysis
  • 4.8. Unmet Needs and Gaps
  • 4.9. Recommended Strategies for Market Entry and Expansion
  • 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.11. Pricing Analysis and Price Dynamics

5. Neurodiagnostics Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Diagnostic Equipment*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Electroencephalogram (EEG)
    • 5.2.4. Magnetoencephalography (MEG)
    • 5.2.5. MRI (Magnetic Resonance Imaging)
    • 5.2.6. CT scan (Computed Tomography)
    • 5.2.7. PET Scan (Positron Emission Tomography)
    • 5.2.8. Sleep Monitoring Devices
    • 5.2.9. Electromyography (EMG) Devices
    • 5.2.10. Polysomnogram (PSG) Devices
    • 5.2.11. Others
  • 5.3. Reagents, Consumables & Accessories
    • 5.3.1. Electrodes
    • 5.3.2. Media
    • 5.3.3. Buffers
    • 5.3.4. Antibodies
    • 5.3.5. Solvents
    • 5.3.6. Others
  • 5.4. Software and Applications

6. Neurodiagnostics Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Epilepsy*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Alzheimer's Disease
  • 6.4. Parkinson's Disease
  • 6.5. Multiple Sclerosis
  • 6.6. Sleep Disorders
  • 6.7. Headache Disorders
  • 6.8. Stroke
  • 6.9. Traumatic Brain Injury (TBI)
  • 6.10. Dementia
  • 6.11. Others

7. Neurodiagnostics Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Neurology Clinics
  • 7.4. Diagnostic Laboratories
  • 7.5. Homecare Settings
  • 7.6. Others

8. Neurodiagnostics Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. UK
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. GE HealthCare*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Siemens Healthineers AG
  • 10.3. Koninklijke Philips N.V.
  • 10.4. FUJIFILM Holdings
  • 10.5. Thermo Fisher Scientific Inc.
  • 10.6. Compumedics Limited
  • 10.7. Natus
  • 10.8. Stratus
  • 10.9. Canon Medical Systems USA, Inc.
  • 10.10. Nihon Kohden Corporation

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us